HETLIOZ (TASIMELTEON) CAPSULES
Live / Applied — Fourth extension granted (statement of use) (as of 19 Sept 2025)
What this means for you
Not registered yet, but its 11 Apr 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97357860
- Mark type
- Design + words
- Filed
- 11 Apr 2022
- Published for opposition
- 29 Aug 2023
- Attorney of record
- Jayme M. Torelli
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations containing tasimelteon for use in the treatment of Autism Spectrum Disorder; Pharmaceutical preparations containing tasimelteon for use in the treatment of Delayed Sleep Phase Disorder; Pharmaceutical preparations containing tasimelteon for use in the treatment of Jet Lag Disorder; Pharmaceutical preparations containing tasimelteon for use in the treatment of depression; Pharmaceutical preparations containing tasimelteon for use in the treatment of Major Depressive Disorder
Owner
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
Prior registrations
Prosecution history
- 25 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 20 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Sept 2025 — SOU EXTENSION 4 GRANTED
- 19 Sept 2025 — SOU EXTENSION 4 FILED
- 19 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Jan 2025 — SOU EXTENSION 3 GRANTED
- 03 Jan 2025 — SOU EXTENSION 3 FILED
- 02 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Oct 2024 — SOU EXTENSION 2 GRANTED
- 01 Oct 2024 — SOU EXTENSION 2 FILED
- 01 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 30 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Mar 2024 — SOU EXTENSION 1 GRANTED